New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
08:22 EDTRTRX, TXMDRetrophin CEO in scandal over Twitter use, TheStreet reports
Retrophin has placed the company's social media activity on "lockdown" following questionable tweets from CEO Martin Shkreli, including one that seemed to hint at a Retrophin acquisition of an approved drug from a private company, reported TheStreet's Adam Feuerstein. The social media blackout also follows the discovery that employees were using Twitter aliases to promote Retrophin and pitch short-sale recommendations of other stocks, including a tweet that singled out TherapeuticsMD (TXMD), the report added. Reference Link
News For RTRX;TXMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2015
09:12 EDTRTRXRetrophin management to meet with Leerink
Subscribe for More Information
08:04 EDTTXMDStifel to hold a conference
Subscribe for More Information
November 16, 2015
08:09 EDTRTRXRetrophin receives EU ODD for sparsentan
Retrophin announced that the European Commission, or EC, has granted sparsentan orphan drug designation for the treatment of focal segmental glomerulosclerosis, or FSGS. Retrophin previously announced in January 2015 that sparsentan received orphan drug designation from the FDA for the treatment of FSGS. Sparsentan is the company's investigational therapeutic agent which acts as both a potent angiotensin receptor blocker, as well as a selective endothelin receptor antagonist, and is currently being evaluated in the Phase 2 DUET trial in FSGS patients. FSGS is a widely recognized cause of end-stage renal disease and there are no approved pharmacologic treatments currently available in the United States or Europe.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use